On June 24, uniQure rose 8.4% in regular trading, trading at approximately $48.00 per share with turnover of $93.05 million. The advance extends the upward momentum following a major FDA regulatory reversal one week prior.

On the news front, uniQure announced on June 23 the launch of a $150 million underwritten public offering, with underwriters granted up to $22.5 million in overallotment options. The market interprets this capital raise as a strong signal that the company is actively preparing for its Biologics License Application submission for AMT-130, its gene therapy targeting Huntington's disease.

The offering follows the pivotal June 17 announcement in which the FDA confirmed that three-year analysis data from AMT-130's Phase I/II study would be acceptable as the primary basis for accelerated BLA approval. That reversal sent shares surging approximately 78% in a single session. The company plans to file the BLA in Q3. RBC Capital Markets subsequently raised its estimated probability of approval to 75% from 50%, citing the unmet medical need and regulatory leniency.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)